M.J. Quiroz Quiroga

M.J. Quiroz Quiroga

Auto-generated profile, based on publicly available information

M.J. Quiroz Quiroga

Glaucoma Unit, Ophthalmology Deparment, Consorci Mar Parc de Salut de Barcelona, Passeig Marítim, 25-29, 08003 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Journal Français d'Ophtalmologie
Verified
Journal Article
Closed access
MQM.J. Quiroz-Quiroga
M.J. Quiroz-Quiroga
HVH. González Valdivia
H. González Valdivia
APAna Palazon-Cabanes
Ana Palazon-Cabanes
JRJOSEP RUBIO-PALAU
JOSEP RUBIO-PALAU
JBJ. Prat Bartomeu
J. Prat Bartomeu

1 December 2020 in Journal Français d'Ophtalmologie
Verified
Journal Article
Closed access
MQM.J. Quiroz Quiroga
M.J. Quiroz Quiroga
CPC. del Prado
C. del Prado
MMM. Morales
M. Morales

18 May 2023 in Journal Français d'Ophtalmologie
Verified
Journal Article
Closed access
AFA. Matheu Fabra
A. Matheu Fabra
MTM. Saint-Gerons Trecu
M. Saint-Gerons Trecu
MQM.J. Quiroz Quiroga
M.J. Quiroz Quiroga
JMJ. Armentia Pérez de Mendiola
J. Armentia Pérez de Mendiola
APA. Martínez Palmer
A. Martínez Palmer
MBM. Martín Baranera
M. Martín Baranera

10 January 2016 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JAJaime Antonio Altamirano
Jaime Antonio Altamirano
IPIvan Federico Pinto
Ivan Federico Pinto
RVRoberto Mauricio Vilches
Roberto Mauricio Vilches
JDJorge Gonzalo Diaz
Jorge Gonzalo Diaz
CSCamilo Sandoval
Camilo Sandoval
AVAndres Vega
Andres Vega
155 Background: The prostatic multiparametric MRI (mpMRI) is the combination of anatomical imaging and functional sequences. Nowadays this technique is still being researched due to its positive published results. The objective of this study is to show our experience in the application of the mpMRI in patients, prior to the TRUS-guided biopsy, and the sensitivity and specificity of its measured parameters and their combination. Methods: Prospective cohort. MpMRI was indicated to patients prior to the TRUS-Guided biopsy. Diffusion, PIRADS, DCE and T2 parameters were observed on the MRIs, and the presence of cancer and Gleason score on the biopsy. Logistic regression test was performed with a 95% confidence interval. We assigned different values, depending of the importance of each factor, applying binominal regression. Results: We registered 73 patients with mpMRI prior to the TRUS-Guided Biopsy, and their results. The cancer detection rate was 60.27% (44 patients). The T2 signal had a sensibility of 81.82% and a specificity of 27.59%, ROC curve 0.54 (CI 0.44 – 0.64). The diffusion has a sensibility of 30% and a specificity of 85.19% with a ROC curve of 0.58 (CI 0.48-0.68). The DCE has a sensibility and specificity of 77.78% and 35.29% respectively, ROC curve of 0.57 (CI 0.42-0.71). By combining the T2, diffusion and DCE parameters, having 2 or more altered values, we obtained a sensibility of 84.62% with a 41.18% specificity, curve of 0.68 (CI 0.54-0.81). The sensitivity and specificity with a PIRADS score ≥ 3 was of 68.42 and 36.36% with a ROC curve of 0.56 (CI 0.36-0.76). With a PIRADS ≥ 4 the sensitivity and specificity was 57.89% and 54.55% respectively. The calculated measured score was assigned as 7 points for altered T2, 8 points for altered diffusion and 5 points for altered DCE. With a total value ≥ 12 the sensitivity of the score was 84.62% with a 41.18% sensitivity, ROC curve 0.68 (CI 0.54-0.81). Conclusions: The use of isolated mpMRI parameters have low performance, whereas this is greatly increased when used combined. The assigned weight of each parameter is a factor to consider and review on the existing scores.